WT Wealth Management Lowers Holdings in VanEck Pharmaceutical ETF $PPH

WT Wealth Management reduced its stake in shares of VanEck Pharmaceutical ETF (NASDAQ:PPH) by 9.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 46,597 shares of the company’s stock after selling 5,095 shares during the period. VanEck Pharmaceutical ETF accounts for about 1.2% of WT Wealth Management’s investment portfolio, making the stock its 25th largest position. WT Wealth Management owned 0.86% of VanEck Pharmaceutical ETF worth $4,099,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently made changes to their positions in PPH. Clal Insurance Enterprises Holdings Ltd acquired a new position in VanEck Pharmaceutical ETF in the second quarter valued at $28,587,000. J.Safra Asset Management Corp raised its holdings in VanEck Pharmaceutical ETF by 1.7% in the second quarter. J.Safra Asset Management Corp now owns 271,620 shares of the company’s stock valued at $23,759,000 after buying an additional 4,566 shares during the period. JPMorgan Chase & Co. lifted its position in VanEck Pharmaceutical ETF by 2,852.2% during the second quarter. JPMorgan Chase & Co. now owns 255,837 shares of the company’s stock valued at $22,503,000 after buying an additional 247,171 shares in the last quarter. Adamsbrown Wealth Consultants LLC lifted its position in VanEck Pharmaceutical ETF by 12.0% during the second quarter. Adamsbrown Wealth Consultants LLC now owns 195,976 shares of the company’s stock valued at $17,238,000 after buying an additional 21,074 shares in the last quarter. Finally, Verity & Verity LLC purchased a new stake in VanEck Pharmaceutical ETF during the second quarter worth approximately $11,551,000.

VanEck Pharmaceutical ETF Stock Up 0.6%

VanEck Pharmaceutical ETF stock opened at $100.79 on Monday. The firm has a fifty day moving average of $96.24 and a 200-day moving average of $90.95. VanEck Pharmaceutical ETF has a 52-week low of $77.67 and a 52-week high of $103.56. The firm has a market capitalization of $1.25 billion, a P/E ratio of 20.21 and a beta of 0.54.

VanEck Pharmaceutical ETF Cuts Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, October 6th. Investors of record on Wednesday, October 1st were issued a $0.3931 dividend. This represents a $1.57 annualized dividend and a yield of 1.6%. The ex-dividend date was Wednesday, October 1st.

VanEck Pharmaceutical ETF Profile

The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.